Amneal scores third biosimilar approval in three months 31-May-2022 By Ben Hargreaves Amneal’s biosimilar to pegfilgrastim-pbbk receives US approval and the company plans to launch the product this year, under the name Fylnetra.
Amneal secures second US biosimilars approval 21-Apr-2022 By Jane Byrne Last week saw the US Food and Drug Administration (FDA) approve the Biologics License Application (BLA) from Amneal Pharmaceuticals Inc for bevacizumab-maly, a biosimilar referencing Avastin, the Roche/Genentech product.